Stockscreener 앱 받기
2.27
2.58%
-0.06
전일 마감가:
$2.33
열려 있는:
$2.33
하루 거래량:
105.03K
Relative Volume:
0.05
시가총액:
$3.97M
수익:
-
순이익/손실:
$-4.23M
주가수익비율:
-0.258
EPS:
-8.8
순현금흐름:
$-1.89M
1주 성능:
+2.25%
1개월 성능:
-10.98%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$2.0707
$2.33
1주일 범위
$2.0707
$2.46
52주 변동 폭
$0.366
$9.40
Lakewood Amedex Biotherapeutics Inc Stock (LABT) Company Profile
명칭
Lakewood Amedex Biotherapeutics Inc
전화
(941) 225-2515
주소
8031 COOPER CREEK BLVD., UNIVERSITY PARK
Compare LABT vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LABT
Lakewood Amedex Biotherapeutics Inc
|
2.27 | 4.13M | 0 | -4.23M | -1.89M | -8.80 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Lakewood Amedex Biotherapeutics Inc 주식(LABT)의 최신 뉴스
Lakewood-Amedex Biotherapeutics (LABT) investor WFI Equity discloses 8.8% ownership stake - Stock Titan
Lakewood-Amedex Raises $7.5M and Lists on NASDAQ, Shedding $1.5M Debt - Minichart
LABT: Q2 net loss rose sharply on higher R&D and G&A costs; liquidity improved after Series C financing - TradingView
Lakewood-Amedex Biotherapeutics Inc. Q2 2026: Revenue $0 Net loss $(3.90M), EPS $(2.75) — 10-Q Summary - TradingView
Lakewood-Amedex (NASDAQ: LABT) raises $7.5M, expands cash yet flags going concern - Stock Titan
Upcoming and recent IPOs – IPOs calendar - Yahoo Finance Australia
Lakewood-Amedex Biotherapeutics (LABT) Stock Trends and Sentiment 2026 $LABT - MarketBeat
Lakewood-Amedex Biotherapeutics announces annual shareholder meeting - Bitget
Lakewood-Amedex (NASDAQ: LABT) seeks 100M share authorization and reverse split power - Stock Titan
Lindesfarne LLC reports 8.582% LABT stake in Lakewood-Amedex Biotherapeutics (LABT) filing - Stock Titan
Lakewood-Amedex Biotherapeutics (LABT) Earnings Date and Reports 2026 $LABT - MarketBeat
Lakewood-Amedex Biotherapeutics Inc. Revenue Breakdown – NASDAQ:LABT - TradingView
Lakewood-Amedex Biotherapeutics, Inc. (LABT) stock price, news, quote and history - Yahoo Finance Singapore
3 Penny Stocks to Watch Today, 7/23/2026 - TipRanks
Lakewood-Amedex Biotherapeutics, Inc. (LABT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Leonard James Deroma Net Worth (2026) - GuruFocus
Lakewood-Amedex Biotherapeutics Inc.Common Stock (Nasdaq:LABT) Stock Quote - FinancialContent
User - The Chronicle-Journal
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Lakewood-Amedex (NASDAQ:LABT) shares jump after Nu-3 news; trading volume more than 200x daily average - TechStock²
Lakewood-Amedex Biotherapeutics Surges as Fresh Nu-3 Data Draws Attention to Its Antibiotic-Resistance Program - Quiver Quantitative
Lakewood-Amedex (LABT) Stock Soars 141% on Breakthrough Nu-3 Resistance Data - parameter.io
Peter Ceccacci Net Worth (2026) - GuruFocus
Kelvin Cooper Net Worth (2026) - GuruFocus
Trending Stocks Today | Lakewood-Amedex Biotherapeutics Shoots up 126.34% - Moomoo
Lakewood-Amedex (LABT) Stock Jumps 141% After Nu-3 Antimicrobial Data Release - CoinCentral
LABT Stock Whipsaws As Traders React To Conference Spotlight - StocksToTrade
LABT Stock Whipsaws As Traders Eye Virtual Forum Exposure - timothysykes.com
Lakewood-Amedex reports resistance data for Nu-3 antimicrobial By Investing.com - Investing.com South Africa
Lakewood-Amedex reports resistance data for Nu-3 antimicrobial - Investing.com
Lakewood-Amedex announces resistance data for Nu-3 - TipRanks
Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria - PR Newswire
Thomas Balzer Net Worth (2026) - GuruFocus
Lakewood-Amedex Biotherapeutics (LABT) Registration filing Summary - Quartr
Lakewood-Amedex Advances Nu-3 Gel Toward Phase 2a Trial - t.co
Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel - Sahm
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) maps Nu-3 iDFU trial path and IP - Stock Titan
Lakewood-Amedex reports preclinical safety data for Nu-3 gel By Investing.com - Investing.com South Africa
Lakewood-Amedex reports preclinical safety data for Nu-3 gel - Investing.com
Lakewood-Amedex announces preclinical data from Phase 2a clinical trial - TipRanks
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
CEO Chat with Dr. Kelvin Cooper, CEO of Lakewood-Amedex Biotherapeutics - scr.zacks.com
Lakewood-Amedex Biotherapeutics Inc. Actuals & Estimates (NASDAQ:LABT) - TradingView
Enterprise value to EBITDA forward of Lakewood-Amedex Biotherapeutics Inc. – NASDAQ:LABT - TradingView
Lakewood-Amedex Biotherapeutics Company Profile & Introduction - Moomoo
Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers - aol.com
Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers - AOL.com
Lakewood-Amedex Biotherapeutics (LABT) Revenue BreakdownMain Composition - Moomoo
Lakewood-Amedex backs reintroduced PASTEUR Act legislation By Investing.com - Investing.com Nigeria
Lakewood-Amedex supports reintroduction of PASTEUR act - TipRanks
Lakewood-Amedex backs reintroduced PASTEUR Act legislation - Investing.com
Lakewood Amedex Biotherapeutics Inc (LABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):